Release Date: 2023-09-14

Current Approach of Diabetes Mellitus in Obese Patients

Sulbiye Karaburgu (Author)

Release Date: 2023-09-14

The current approach to managing diabetes mellitus in obese patients focuses on a comprehensive strategy that addresses both conditions simultaneously. Central to this approach is weight management through lifestyle modifications, including dietary changes and increased physical activity. Caloric restriction, with an emphasis on balanced nutrition that limits simple sugars and unhealthy fats while promoting fiber-rich [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Perspective on Diabetes Mellitus in Clinical Sciences
First Page77
Last Page103
DOIhttps://doi.org/10.69860/nobel.9786053359111.8
ISBN978-605-335-911-1 (PDF)
LanguageENG
Page Count27
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

The current approach to managing diabetes mellitus in obese patients focuses on a comprehensive strategy that addresses both conditions simultaneously. Central to this approach is weight management through lifestyle modifications, including dietary changes and increased physical activity. Caloric restriction, with an emphasis on balanced nutrition that limits simple sugars and unhealthy fats while promoting fiber-rich foods, plays a crucial role. Regular exercise helps improve insulin sensitivity and facilitates weight loss. Pharmacotherapy may include medications that not only lower blood glucose levels but also aid in weight reduction, such as GLP-1 receptor agonists and SGLT-2 inhibitors. These agents have shown benefits beyond glycemic control by promoting weight loss and reducing cardiovascular risk factors. Bariatric surgery is considered for severely obese individuals with diabetes which is difficult to control with lifestyle modifications and medications alone. It can lead to significant weight loss and often results in remission or improvement of diabetes. Continuous monitoring of blood glucose levels, along with regular assessments of lipid profiles, kidney function, and cardiovascular risk factors, guides treatment adjustments and helps prevent complications. Patient education and ongoing support are essential to promote adherence to treatment plans and empower individuals to manage both diabetes and obesity effectively. Integrating these approaches ensures a holistic and personalized management strategy tailored to the unique needs of obese patients with diabetes mellitus.

Sulbiye Karaburgu (Author)
Assistant Professor, Karamanoglu Mehmetbey University
https://orcid.org/0000-0002-7916-8257

  • Garvey WT, Umpierrez GE, Dunn JP, Kwan AYM, Varnado OJ, Konig M, vd. Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes Obes Metab. 2022;24(8):1411-22.

  • Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, vd. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440-50.

  • Sims EA, Danforth E, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973;29:457-96.

  • Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. Kasım 2014;2(11):911-22.

  • Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6.

  • Esquivel MA, Lansang MC. Optimizing diabetes treatment in the presence of obesity. Cleve Clin J Med. 2017;84(7 Suppl 1):S22-9.

  • Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab. Aralık 2001;3(6):410-6.

  • Burguera B, Ali KF, Brito JP. Antiobesity drugs in the management of type 2 diabetes: A shift in thinking? Cleve Clin J Med. 2017;84(7 Suppl 1):S39-46.

  • McAdam-Marx C, Mukherjee J, Bellows BK, Unni S, Ye X, Iloeje U, vd. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Clin Pract. 2014;103(3):402-11.

  • Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest. 2008;118(7):2583-91.

  • Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38(6):1161-72.

  • Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, vd. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2016;22(1):84-113.

  • McFarlane SI. Antidiabetic medications and weight gain: implications for the practicing physician. Curr Diab Rep. 2009;9(3):249-54.

  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet Lond Engl. 1998;352(9131):854-65.

  • Cabrera J, Emir B, Dills D, Murphy TK, Whalen E, Clair A. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin. 2012;28(6):1027-37.

  • Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab. 2007;33(3):169-75.

  • van Dieren S, Czernichow S, Chalmers J, Kengne AP, de Galan BE, Poulter N, vd. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab. 2012;14(5):464-9.

  • Toft UN, Kristoffersen LH, Aadahl M, von Huth Smith L, Pisinger C, Jørgensen T. Diet and exercise intervention in a general population--mediators of participation and adherence: the Inter99 study. Eur J Public Health. 2007;17(5):455-63.

  • Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care. 1988;11(7):567-73.

  • Maclean PS, Bergouignan A, Cornier MA, Jackman MR. Biology’s response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol. 2011;301(3):R581-600.

  • Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, vd. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-604.

  • de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Ann Nutr Metab. 2007;51(2):134-8.

  • Hargraves I, LeBlanc A, Shah ND, Montori VM. Shared Decision Making: The Need For Patient-Clinician Conversation, Not Just Information. Health Aff Proj Hope. 2016;35(4):627-9.

  • Kahan S, Fujioka K. Obesity Pharmacotherapy in Patients With Type 2 Diabetes. Diabetes Spectr Publ Am Diabetes Assoc. 2017;30(4):250-7.

  • ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, vd. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S128-39.

  • Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet Lond Engl. 2016;387(10031):1947-56.

  • Cai X, Yang W, Gao X, Zhou L, Han X, Ji L. Baseline Body Mass Index and the Effi cacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis. PloS One. 2016;11(12):e0166625.

  • Ross SA, Dzida G, Vora J, Khunti K, Kaiser M, Ligthelm RJ. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin. 2011;27(7):1431-8.

  • Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence. 2017;11:1103-17.

  • Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7(17):354-95.

  • Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes Targets Ther. 2013;6:453-67.

  • Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2014;5(2):355-66.

  • Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr Publ Am Diabetes Assoc. 2017;30(3):202-10.

  • Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014;34(11):1174-86.

  • Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. J Clin Pharm Ther. 2020;45 Suppl 1(Suppl 1):17-27.

  • Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7(11):2294-300.

  • Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019;128:94-105.

  • Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017;136(9):849-70.

  • Giugliano D, Maiorino MI, Bellastella G, Longo M, Chiodini P, Esposito K. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab. 2019;21(11):2576-80.

  • Onge ES, Miller SA, Motycka C. Liraglutide (Saxenda®) as a Treatment for Obesity. Food Nutr Sci. 2016;7(4):227-35.

  • Scarpello JHB, Howlett HCS. Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008;5(3):157-67.

  • American Diabetes Association. Standards of Medical Care in Diabetes-2019 Abridged for Primary Care Providers. Clin Diabetes Publ Am Diabetes Assoc. 2019;37(1):11-34.

  • Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-76.

  • Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019;8(2):156-64.

  • Scheen AJ. Pharmacodynamics, effi cacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33-59.

  • Butler J, Handelsman Y, Bakris G, Verma S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020;22(4):604-17.

  • Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 2019;79(3):219-30.

  • Haddad F, Dokmak G, Bader M, Karaman R. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life Basel Switz. 14 2023;13(4):1012.

  • Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity. Cardiovasc Res. 2022;cvac176.

  • Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Expert Opin Pharmacother. 2014;15(17):2487-500.

  • Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(5):262-9.

  • Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol.2012;8(12):728-42.

  • Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021;38(6):2821-39.

  • Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon Off J Int Soc Toxinology. 2012;59(4):464-71.

  • Tucker T, Turley S, Bollinger K, Beck J, Hrometz S. Comparing the GLP-1 Receptor Agonists: Byetta®, Victoza® and once-weekly BydureonTM. Pharm Wellness Rev. 2019;4(1):16-20.

  • Rotenstein L, Kozak B, Shivers J, Yarchoan M, Close J, Close K. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We? Clin Diabetes. 2012;30:44-53.

  • Painter NA, Morello CM, Singh RF, McBane SE. An evidence-based and practical approach to using BydureonTM in patients with type 2 diabetes. J Am Board Fam Med JABFM. 2013;26(2):203-10.

  • Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016;7(2):92-107.

  • Maselli D, Atieh J, Clark MM, Eckert D, Taylor A, Carlson P, vd. Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial. Obes Silver Spring Md. 2022;30(8):1608-20.

  • Elkinson S, Keating GM. Lixisenatide: fi rst global approval. Drugs. 2013;73(4):383-91.

  • Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:2042018821997320.

  • Christensen M, Miossec P, Larsen BD, Werner U, Knop FK. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opin Drug Discov. 2014;9(10):1223-51.

  • Ryan DH. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice? J Obes Metab Syndr. 2021;30(3):196-208.

  • Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159-66.

  • Dhillon S. Semaglutide: First Global Approval. Drugs. 2018;78(2):275-84.

  • Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med Off Publ Am Fed Clin Res. 2022;70(1):5-13.

  • Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-62.

  • Bradley CL, McMillin SM, Hwang AY, Sherrill CH. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. Ann Pharmacother. 2022;10600280221134128.

  • Dhirani D, Shahid A, Mumtaz H. A new kind of diabetes medication approved by the FDA: is there hope for obesity? Int J Surg Lond Engl. 2023;109(2):81-2.

  • Baker DE, Walley K, Levien TL. Tirzepatide. Hosp Pharm. 2023;58(3):227-43.

  • Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564-600.

  • Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127-42.

  • Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12(9):1439-51.

  • Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest. 1994;24 Suppl 3:3-10.

  • Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4(5):329-35.

  • van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alphaglucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28(1):154-63.

  • Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642-53.

  • Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol. 2019;10:389.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!